The size of India’s insulin market was an estimated Rs 4,404 crore in April this year, with Indian players making steady entry into a market once dominated by Big pharma.
Afrezza, world’s only rapid-acting, inhaled insulin for type 1 & type 2 diabetes patients & manufactured by MannKind, received CDSCO approval this week.
Novo Nordisk scientists have synthesised an insulin molecule that specifically targets glucose in blood, instead of other sugars like fructose, to aid treatment of all types of diabetes.
Doctors Without Borders says new class of drugs & insulin devices could be leading to ‘exorbitant corporate profiteering’. Study published in Journal of the American Medical Association.
Icodec has been touted as a therapy that could eliminate the need for daily or mealtime insulin injections for people with severe diabetes. It has not been approved by any country so far.
Danish pharmaceutical giant Novo Nordisk has said it is set to apply for regulatory approval of its once-a-week insulin drug, Icodec. Results of Phase-3 clinical trial shown 'promising results'.
UK patients may soon be covered for the device, which measures blood glucose, computes amount of insulin needed and then pumps that exact amount into bloodstream.
As Park Street now anticipates the Christmas lights, Bangla cinema eyes a harmony. Colliding heritage, devotion and some detective grit, the year-ender comes with a rediscovery.
Clean energy is “no longer the sideshow, it is the show”, BVR Subrahmanyam told the Odisha summit, warning India to lead the global shift or risk others’ tech dominance.
Dubai airshow crash & pilot death have rekindled concerns over pilot safety, and need for smarter automated systems that can step in when G-forces, temporary loss of consciousness hit the pilot.
None of Pakistan’s PMs has lasted 5 years. That the current PM has given Asim Munir 5 years shows that of all military dictatorships history has seen, Pakistan’s is most creative.
COMMENTS